Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report details a specific share repurchase transaction executed on May 21, 2013, following shareholder authorization granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 190,185 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,718.0 pence per share; lowest price paid was 1,709.0 pence per share.
- Treasury Holdings (Settled): 499,316,327 shares, representing 9.20% of total issued share capital.
- Treasury Holdings (Including Unsettled): 500,092,012 shares, representing 10.15% of total voting rights.
- Shares in Issue (Excluding Treasury): 4,927,458,828 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 190,185 shares on May 21, 2013. Consequently, the percentage of total voting rights held in Treasury increased to 10.15% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (499,316,327 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.15% held in Treasury including unsettled shares).
- Check the denominator for shareholder notification thresholds (4,927,458,828 shares in issue).
- Review the price paid per share (1,709.0 to 1,718.0 pence) against market prices on May 21, 2013.